Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
25 September 2024 - 1:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction
notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Wendy
Becker
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Purchase
of 463 Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.5650
|
463
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-20
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Elizabeth
(Liz) McKee Anderson
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 223 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
223
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Charles
Bancroft
|
|
b)
|
Position/status
|
Senior
Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D79343
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 1,801 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
1,801
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Hal
Barron
|
|
b)
|
Position/status
|
Non-Executive
Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 224 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
224
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Anne
Beal
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 224 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
224
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Hal
Dietz
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 224 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
224
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr
Jesse Goodman
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 224 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
224
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr
Jeannie Lee
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 224 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
224
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr
Vishal Sikka
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Purchase
of 773 ADSs
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.0114
|
773
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date of
the transaction
|
2024-09-23
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
24, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Dec 2024 to Jan 2025
GSK (NYSE:GSK)
Historical Stock Chart
From Jan 2024 to Jan 2025
